Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27Kip1

Zhao, Yi; Tang, Qiyun; Ni, Runzhou; Huang, Xiaodong; Wang, Yuchan; Lu, Cuihua; Shen, Aiguo; Wang, Yingying; Li, Chunmiao; Yuan, Qin; Chen, Hongwei; Cheng, Chun; He, Song

doi:10.1016/j.humpath.2012.03.030

Cited by 35 publications

(29 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consistent with this notion, significant overexpression of FBXO5 was detected in ovarian tumour tissues 97 . Overexpression of FBXO5 was associated with a high histological grade and worse survival in ovarian cancer 98 , and it was positively correlated with stage and poor outcome in hepatocellular carcinoma 99 . Biochemically, FBXO5 has been shown to govern cell cycle progression to S phase and mitosis via stabilizing APC/C ubiquitin substrates that have oncogenic activity, such as cyclin A, cyclin B or securin, by binding to APC/C co-activator proteins to inhibit APC/C activation 100 .…”

Section: Oncogenic F-box Proteinsmentioning

confidence: 96%

Roles of F-box proteins in cancer

et al. 2014

View full text Add to dashboard Cite

F-box proteins, which are the substrate-recognition subunits of SKP1–cullin 1–F-box protein (SCF) E3 ligase complexes, have pivotal roles in multiple cellular processes through ubiquitylation and subsequent degradation of target proteins. Dysregulation of F-box protein-mediated proteolysis leads to human malignancies. Notably, inhibitors that target F-box proteins have shown promising therapeutic potential, urging us to review the current understanding of how F-box proteins contribute to tumorigenesis. As the physiological functions for many of the 69 putative F-box proteins remain elusive, additional genetic and mechanistic studies will help to define the role of each F-box protein in tumorigenesis, thereby paving the road for the rational design of F-box protein-targeted anticancer therapies.

show abstract

Section: Oncogenic F-box Proteinsmentioning

confidence: 96%

Roles of F-box proteins in cancer

et al. 2014

View full text Add to dashboard Cite

show abstract

“…Skp2 targets the three Cip/Kip family members (p21, p27, and p57) for degradation in tumors [214,218]. Skp2 itself is a target of ubiquitin-degradation cascade through recognition by the APC/C Cdh1 , and is often deregulated in HCC (Figure 7) [219,220,221]. In addition, Skp2 expression is controlled by several transcription factors deregulated in HCC, downstream of various signaling pathways [222].…”

Section: Deregulations Of Cell Cycle Genes In Hccmentioning

confidence: 99%

The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations

Bisteau

Caldez

Kaldis

2014

Cancers

View full text Add to dashboard Cite

The liver acts as a hub for metabolic reactions to keep a homeostatic balance during development and growth. The process of liver cancer development, although poorly understood, is related to different etiologic factors like toxins, alcohol, or viral infection. At the molecular level, liver cancer is characterized by a disruption of cell cycle regulation through many molecular mechanisms. In this review, we focus on the mechanisms underlying the lack of regulation of the cell cycle during liver cancer, focusing mainly on hepatocellular carcinoma (HCC). We also provide a brief summary of novel therapies connected to cell cycle regulation.

show abstract

“…FBXO5, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation. FBXO5 overexpression causes mitotic catastrophe and genomic instability and potentially contributes to tumorigenesis (20). FBXO11 targets BCL6 for degradation and functions as a tumor suppressor in diffuse large B-cell lymphomas (21).…”

Section: The F-box Protein Familiesmentioning

confidence: 99%

“…P27 is a negative regulator of the cell cycle that plays an important role in tumor suppression. Loss of p27 results in uncontrolled proliferation and promotes tumor progression (20,27). Taken together, these findings indicate that the SKP2-mediated reduction, as a result of enhanced degradation of tumor suppressor p27, contribute to the development of cancers including esophageal cancer (28).…”

Section: The Emerging Roles Of Scf Skp2 E3 Ligases In Ecmentioning

confidence: 99%

Involvement of F-box proteins in esophageal cancer (Review)

Gong

Huang

Huo

2016

International Journal of Oncology

View full text Add to dashboard Cite

The F-box proteins (FBPs) in esophageal tumorigenesis are pivotal as they govern a broad array of basic physiological responses including cell growth, cell death and DNA damage repair. Esophageal cancer (EC) is a common and highly aggressive cancer worldwide. Aberrant stabilization of crucial proteins participates in esophageal tumorigenesis. Recently, growing evidence has shown that FBPs play a critical role in oncogenesis, invasion, metastasis and prognosis assessment of EC. In this review we summarized published data on the roles of known FBPs, their respective substrates and the key signaling pathways, in the development of EC, aiming to uncover new ways for the rational design of targeted therapies in EC.

show abstract

Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27Kip1

Cited by 35 publications

References 17 publications

Roles of F-box proteins in cancer

Roles of F-box proteins in cancer

The Complex Relationship between Liver Cancer and the Cell Cycle: A Story of Multiple Regulations

Involvement of F-box proteins in esophageal cancer (Review)

Contact Info

Product

Resources

About